Research around β2-glycoprotein I: A major target for antiphospholipid antibodies

Autoimmunity

Volumn 38, Issue 5, 2005, Pages 377-381

  Atsumi, Tatsuya ^a   Amengual, Olga ^a   Yasuda, Shinsuke ^a   Matsuura, Eiji ^b   Koike, Takao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

APS; Fibrinolysis; Nicked 2GPI; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 10A; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; PLASMIN; PROCOAGULANT;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CELL STIMULATION; DISEASE MARKER; FIBRINOLYSIS; HUMAN; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; THROMBOPHILIA;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; AUTOIMMUNE DISEASES; BETA 2-GLYCOPROTEIN I; GLYCOPROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHOLIPIDS; PROTEIN BINDING;

EID: 25444450310     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.1080/08916930500124312     Document Type: Article

References (41)

1. Schultze HE, Heideke K, Haput H. Uber ein bisher ubekanntes niedermolekulars β2-Globulin des Humanserums. Naturwissenschaften 1961;48:719.
2. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-1547.
3. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that induces a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4124.
4. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-178.
5. Ohkura N, Hagihara Y, Yoshimura. T, Goto Y, Kato H. Plasmin can reduce the function of human β2 glycoprotein I by cleaving domain V into a nicked form. Blood 1998;91:4173-4179.
6. Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma β2-glycoprotein I. Proc Natl Acad Sci USA 1984;81:3640-3644.
7. Kato H, Enjyoji K. Amino acid sequence and location of the disulfide bonds in bovine β2-glycoprotein I: The presence of five Sushi domains. Biochemistry 1991;30:11687-11694.
8. Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, Derksen RH, Kroon J, Gros P. Adhesion mechanism of human β(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999;18:5166-5174.
9. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R. Crystal structure of human beta2-glycoprotein I: Implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999;18:6228-6239.
10. Matsuura E, Inagaki J, Kasahara H, Yamamoto D, Atsumi T, Kobayashi K, Kaihara K, Zhao D, Ichikawa K, Tsutsumi A, Yasuda T, Triplett DA, Koike T. Proteolytic cleavage of β2-glycoprotein I: Reduction of antigenicity and the structural relationship. Int Immunol 2000;12:1183-1192.
11. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457-462.
12. Tsutsumi A, Ichikawa K, Matsuura E, Sawada K, Koike T. Heterogeneous behavior of anti-β2-glycoprotein I antibodies on various commercially available enzyme immunoassay plates coated with β2-glycoprotein I. J Rheumatol 2000;27:391-396.
13. Shi W, Chong B, Hogg P, Chesterman C. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993;70:342-345.
14. Schousboe I, Rasmussen MS. Synchronized inhibition of the phospholipid mediated autoactivation of Factor XII in plasma by β2-glycoprotein I and anti-β2-glycoprotein I. Thromb Haemost 1995;73:798-804.
15. Nimpf J, Wurm H, Kostner GM. β2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987;63:109-114.
16. Ieko M, Ichikawa K, Triplett DA, Matsuura E, Atsumi T, Sawada K, Koike T. Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999;42:167-174.
17. Forastiero RR, Martinuzzo ME, Lu L, Broze GJ. Autoimmune antiphospholipid antibodies impair the inhibition of activated factor X by protein Z/protein Z-dependent protease inhibitor. J Thromb Haemost 2003;1:1764-1770.
18. Nakaya Y, Schaefer EJ, Brewer HBJ. Activation of human post heparin lipoprotein lipase by apolipoprotein H (β2-glycoprotein I). Biochem Biophys Res Commun 1980; 95:1168-1172.
19. Wurm H, Beubler E, Polz E, Holasek A, Kostner G. Studies on the possible function of β2-glycoprotein-I: Influence in the triglyceride metabolism in the rat. Metabolism 1982; 31:484-486.
20. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107:569-573.
21. Chonn A, Semple SC, Cullis PR. β2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. J Biol Chem 1995;270:25845-25849.
22. Manfredi AA, Rovere P, Galati G, et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998; 41:205-214.
23. Manfredi AA, Rovere P, Heltai S, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of β2-glycoprotein I. Arthritis Rheum 1998;41:215-223.
24. Takeuchi R, Atsumi T, Ieko M, Takeya H, Yasuda S, Ichikawa K, Tsutsumi A, Suzuki K, Koike T. Coagulation and fibrinolytic activities in 2 siblings with beta(2)-glycoprotein I deficiency. Blood 2000;96:1594-1595.
25. 2-glycoprotein I deficiency: Prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 2000;152: 337-346.
26. Hashimoto Y, Kawamura M, Ichikawa K, Suzuki T, Sumida T, Yoshida S, Matsuura E, Ikehara S, Koike T. Anticardiolipin antibodies in NZW × BXSB F1 mice. A model of anti-phospholipid syndrome. J Immunol 1992;149:1063-1068.
27. Suzuki T, Takabayashi K, Ichikawa K, Itou I, Ishiguro N, Yoshiki T, Koike T. Effects of monoclonal anticardiolipin antibody on pregnant mice. J Rheumatol 1996;23:83-86.
28. George J, Blank M, Gilburd B, Hojnik M, Shenkman B, Tamarin I, Varon D, Matsuura E, Koike T, Shoenfeld Y. Immunologic characterization and functional properties of murine antibodies raised against deleted mutants of human β2-glycoprotein I. Int Immunol 1997;9:913-921.
29. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GI, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999;99:1997-2002.
30. Mann K. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999;82:165-174.
31. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994;153:1328-1332.
32. Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Upregulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 1997;77:222-223.
33. Cuadrado MJ, Lopez-Pedreira C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome. A pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997;40:834-841.
34. Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276-281.
35. Bohgaki M, Atsumi T, Yamashita Y, Yasuda S, Sakai Y, Furusaki A, Bohgaki T, Amengual O, Amasaki Y, Koike T. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2glycoprotein I antibodies. Int Immunol 2004;16:1633-1641.
36. 2-glycoprotein I: Reduction of antigenicity and the structural relationship. Intern Immunol 2000;12:1183-1192.
37. Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG. β2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999;81:87-95.
38. Itoh Y, Inuzuka K, Kohno I, Wada H, Shiku H, Ohkura N, Kato H. Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with lupus anticoagulant: Measurement with a monoclonal antibody specific for a nicked form of domain V. J Biochem (Tokyo) 2000;128:1017-1024.
39. Yasuda S, Atsumi T, Ieko M, Matsuura E, Kobayashi K, Inagaki J, Kato H, Tanaka H, Yamakado M, Akino M, Saitou H, Amasaki Y, Jodo S, Amengual O, Koike T. Nicked beta2-glycoprotein I: A marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004;103:3766-3772.
40. Takeuchi R, Atsumi T, Ieko M, Amasaki Y, Ichikawa K, Koike T. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: Possible mechanism for thrombosis in patients with antiphospholipid syndrome. Br J Haematol 2002;119:781-788.
41. Ieko M, Ichikawa K, Atsumi T, Takeuchi R, Sawada KI, Yasukouchi T, Koike T. Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies on extrinsic fibrinolysis. Semin Thromb Hemost 2000;26:85-90.